Gilead Sciences (GILD) Earnings Date & Reports

Key Takeaways

• Gilead Sciences (NASDAQ: GILD) is expected to report Q2 2026 results on or around August 6, 2026, after market close.
• Consensus GAAP earnings per share (EPS) estimates range from approximately -$6.94 to -$7.14, reflecting an estimated $11.5 billion one-time in-process research and development (IPR&D) charge tied to recent acquisitions.
• Non-GAAP EPS — which excludes the acquisition-related charge — is expected near $2.15, up from $2.01 in the same quarter last year.
• Revenue is projected between $7.37 billion and $7.41 billion, representing year-over-year growth of roughly 4% to 5% from Q2 2025's $7.08 billion.
• The underlying business continues to show strength, with the HIV franchise, oncology portfolio, and new specialty launches driving growth.
• Management raised full-year 2026 revenue guidance to $30.0–$30.4 billion following the Q1 beat, and investors will focus on whether that momentum carried into the second quarter.

Earnings Context and Why It Matters

Gilead Sciences enters this earnings report at a uniquely complex moment. The company closed several major acquisitions in the first half of 2026 — including Arcellx (up to $7.8 billion for its CAR-T platform), Tubulis GmbH ($3.15 billion for antibody-drug conjugate technology), and Ouro Medicines — collectively triggering an estimated $11.5 billion IPR&D accounting charge that will dominate the GAAP income statement. While the headline loss will appear dramatic, it reflects non-cash acquisition accounting rather than operational deterioration. For investors, the real story lies beneath the surface: the strength of Gilead's core HIV franchise, the growth trajectory of oncology drug Trodelvy, and the early performance of recently launched therapies. How management frames its post-acquisition outlook will be critical in shaping market sentiment.

Earnings Expectations

Analyst consensus points to a stark disconnect between GAAP and non-GAAP results for Q2 2026. On a GAAP basis, the consensus EPS estimate sits at approximately -$6.94 to -$7.14, weighed down almost entirely by the IPR&D charge. Excluding that charge, non-GAAP EPS estimates land closer to $2.15, which would represent year-over-year growth from the $2.01 reported in Q2 2025. Revenue expectations range from $7.37 billion to $7.41 billion, up from $7.08 billion a year ago, suggesting the Street anticipates continued top-line momentum.

Key metrics under scrutiny will include Biktarvy sales (which reached $3.4 billion in Q1, up 7% year-over-year), Trodelvy revenue ($402 million in Q1, up 37%), and the ramp of Libdelzi, Gilead's treatment for primary biliary cholangitis (a chronic liver disease), which generated $133 million in Q1 and captured over 50% of the U.S. second-line market. The company's HIV pre-exposure prophylaxis (PrEP) business, led by Descovy and the newer Yes2Go, will also be closely watched after 87% year-over-year U.S. PrEP growth in Q1.

Gilead has a strong track record of exceeding consensus estimates, having beaten EPS expectations in six of the last seven quarters. In Q1 2026, the company posted EPS of $2.03 against a $1.91 consensus and revenue of $6.96 billion versus expectations of $6.91 billion.

AI Screener

For investors seeking to identify stocks with similar earnings momentum or technical setups ahead of major events like Gilead's Q2 report, Tickeron's AI Screener offers a practical solution. This AI-powered stock and ETF discovery tool enables traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-driven trading signals. Whether scanning for breakout candidates, trending names, or stocks exhibiting specific fundamental characteristics, the AI Screener helps streamline market research efficiently. Explore the tool to uncover trade ideas aligned with your strategy.

Market Reaction and Investor Sentiment

Gilead shares have traded in a range of roughly $108 to $157 over the past 52 weeks and were near $130 heading into this earnings period — well below the consensus analyst price target of approximately $159. The stock carries a consensus "Moderate Buy" rating, with 26 of 29 covering analysts recommending a buy. Sentiment appears cautiously optimistic, with several firms — including Truist, HSBC, and Citigroup — raising price targets in recent months.

However, risk factors heading into the report are notable. The sheer size of the GAAP loss could generate negative headlines that temporarily pressure the stock, even though the charge is widely anticipated. Additionally, any signs of slowing momentum in the HIV franchise or weaker-than-expected Trodelvy growth would likely weigh on the shares. On the other hand, if non-GAAP results come in ahead of expectations and guidance is reaffirmed or raised, the stock could respond favorably as the market refocuses on underlying earnings power and cash flow generation.

Forward Outlook and Key Factors to Monitor

Looking beyond Q2, the investment narrative for Gilead will pivot on several identifiable catalysts — and the company's ability to execute across its expanding portfolio while absorbing recent acquisitions.

First, the HIV franchise remains the financial backbone of the company. Biktarvy continues to hold over 52% of the U.S. market share, and management raised its full-year 2026 HIV sales growth forecast to approximately 8% after Q1. Investors should monitor whether Biktarvy's market position holds and whether Yes2Go — now guided to approximately $1.0 billion for the year — sustains its rapid adoption trajectory. Any deceleration in these core products would reverberate across the entire investment case.

Second, Trodelvy's growth story is entering a pivotal phase. With a 37% year-over-year revenue jump in Q1 and multiple Phase 3 clinical trial readouts expected in the second half of 2026, the oncology drug represents Gilead's most visible non-HIV growth engine. Regulatory decisions on label expansions could meaningfully expand the addressable patient population.

Third, the integration of newly acquired assets — particularly Arcellx's CAR-T cell therapy platform and Tubulis's antibody-drug conjugate technology — will shape the long-term pipeline narrative. Investors should listen for updates on clinical timelines, expected regulatory milestones, and any early revenue contributions from these acquisitions.

Finally, cost management and margin trends matter. Gilead delivered a product gross margin of 87% and an operating margin of 47% in Q1. Maintaining or improving those levels while absorbing R&D spending from the new acquisitions will be an important signal of operational discipline. The company returned over $1.4 billion to shareholders in Q1 through dividends and buybacks; any change in capital allocation strategy could also influence sentiment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations